Institute Of Hematology & Blood Diseases Hospital, China

This study tests a drug called inotuzumab ozogamicin in 31 adults with a type of leukemia (Ph-negative ALL) who achieved remission after initial chemotherapy but still have tiny amounts of cancer cells (minimal residual disease, or MRD). The goal is to see if the drug can clear t…

This study tests whether a transplant of umbilical cord blood can slow the progression of ALS, a fast-moving nerve disease. Eight adults with early-stage ALS will receive the transplant and be monitored for safety and changes in muscle strength, breathing, and nerve damage. The g…

This study compares two chemotherapy regimens for adults aged 60-75 newly diagnosed with acute myeloid leukemia (AML) who can tolerate intensive treatment. About 90 participants will be randomly assigned to one of three groups to see which approach leads to better event-free surv…

This study aimed to test a drug called CM-336 (a BCMA/CD3 bispecific antibody) in people with AL amyloidosis whose disease came back or didn't respond well to initial treatment. The goal was to see if the drug could improve blood markers of the disease. However, the trial was wit…

This study tests a new treatment for people with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The treatment combines two immune-based approaches: a bispecific antibody and CAR-T cells, aiming to boost the…

This study tested a new treatment called BCMA CAR-T cell therapy for people with a high-risk type of multiple myeloma who still had signs of cancer after their first stem cell transplant. The goal was to see if the therapy could safely clear the remaining cancer cells. The study …

This study aimed to test a new drug (CM313) combined with a chemotherapy plan inspired by children's treatment for adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). The goal was to see if the combination was safe and improved remission rates. However, the t…

This study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy (cytarabine) in 39 adults newly diagnosed with mantle cell lymphoma who have not received prior treatment. The goal is to see how well this appr…

This study compares two chemotherapy regimens for adults aged 60-75 with acute myeloid leukemia (AML) who can handle intensive treatment. The goal is to see if a new combination (HAV) works better than the standard DAV/IAV regimen at improving remission and survival. About 41 par…

This study tested whether the drug daratumumab can eliminate tiny amounts of leukemia cells that remain after standard chemotherapy in adults with T-cell acute lymphoblastic leukemia (T-ALL). These remaining cells, called minimal residual disease (MRD), raise the risk of the canc…

This study looks at whether tracking a specific genetic change called c-Kit mutation can help doctors better predict if acute myeloid leukemia (AML) will come back after treatment. Researchers will compare this method with current monitoring techniques. The study was withdrawn be…

This study follows 2,000 people who stored umbilical cord blood at Tianjin Cord Blood Bank to see how their health changes over time. Researchers will contact participants to check on their health status. The goal is to learn more about the long-term health of people who have sto…

This study is gathering information from 500 male patients aged 12 and older with severe hemophilia A or B in China. Researchers are measuring the disease's burden, treatment costs, and how care varies across different regions and centers. The goal is to identify gaps in care and…